Therapy Areas: Autoimmune
Adicet Bio doses first patient in Phase 1 trial of ADI-001 for lupus nephritis
18 November 2024 - Biotechnology company Adicet Bio Inc (Nasdaq: ACET) announced on Monday the first dosing of a lupus nephritis (LN) patient in its Phase 1 trial for ADI-001, an allogeneic gamma delt...
Pulmatrix announces merger with Cullgen to advance targeted protein degradation
13 November 2024 - Clinical-stage biopharmaceutical company Pulmatrix Inc (Nasdaq: PULM) announced on Wednesday that it plans to merge with Cullgen Inc, a privately-held company that specialises in ta...
Faron Pharmaceuticals files patent for soluble Clever-1 in autoimmune disease treatment
11 November 2024 - Biopharmaceutical company Faron Pharmaceuticals Ltd (AIM: FARN) (First North: FARON) announced on Monday that it has filed a patent application for the use of soluble Clever-1 to ta...
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business
5 November 2024 - Nektar Therapeutics (Nasdaq: NKTR), a biotechnology company focused on the discovery and development of novel therapies to treat autoimmune disorders, announced on Monday that it has...
OSE Immunotherapeutics' Lusvertikimab shows promise in ulcerative colitis
4 November 2024 - French biotechnology company OSE Immunotherapeutics SA (Euronext Paris:OSE) on Monday announced positive results from the Phase 2 CoTikiS study of Lusvertikimab (OSE-127), an anti-IL...
Hemogenyx Pharmaceuticals schedules Phase i clinical trial for HEMO-CAR-T
30 October 2024 - Hemogenyx Pharmaceuticals plc (LSE: HEMO), a biopharmaceutical company dedicated to developing innovative therapies for blood diseases, on Wednesday announced the timeline for openin...